ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
Oropharyngeal pain | 22.02.05.022; 07.05.05.004 | - | - | |
Acute kidney injury | 20.01.03.016 | - | - | |
Ocular ischaemic syndrome | 24.04.09.005; 06.07.02.005 | - | - | Not Available |
Drug-induced liver injury | 12.03.01.044; 09.01.07.023 | 0.002131% | | Not Available |
Sinus node dysfunction | 02.03.03.017 | - | - | |
Multiple organ dysfunction syndrome | 08.01.03.057 | 0.000278% | | |
Liver function test increased | 13.03.01.044 | 0.000533% | | Not Available |
Carcinoembryonic antigen increased | 13.22.01.009 | 0.000533% | | Not Available |
Lung carcinoma cell type unspecified recurrent | 22.08.01.018; 16.19.02.005 | 0.000208% | | Not Available |
Malignant pleural effusion | 16.32.03.014; 22.05.04.001 | 0.000208% | | Not Available |
Metastases to adrenals | 16.22.02.012; 05.01.04.007 | 0.000799% | | Not Available |
Metastases to bone | 16.22.02.005; 15.09.03.006 | 0.001598% | | Not Available |
Metastases to lymph nodes | 16.22.02.006; 01.09.01.015 | 0.000208% | | Not Available |
Metastases to pleura | 16.22.02.022; 22.05.04.002 | 0.000278% | | Not Available |
Metastases to the mediastinum | 22.09.03.009; 16.22.02.027 | 0.000533% | | Not Available |
Tumour marker increased | 13.22.01.017 | 0.000533% | | Not Available |
Metastases to meninges | 17.02.10.012; 16.22.02.003 | 0.000764% | | Not Available |
Lymphangiosis carcinomatosa | 24.09.02.007; 16.22.02.009; 01.09.01.027 | 0.000208% | | Not Available |
Acquired gene mutation | 08.01.10.002 | 0.005062% | | Not Available |
Infectious pleural effusion | 22.05.01.004; 11.01.09.011 | 0.000533% | | Not Available |
EGFR gene mutation | 08.01.10.004 | 0.000417% | | Not Available |
Cutaneous symptom | 23.07.04.023 | 0.000533% | | Not Available |